Organogenesis Q2 revenue $121.4M (-1% YoY); net income falls 58% to $8.7M

Organogenesis Holdings Inc.

2022-Q2 EPS reported $0.06 revenue$218,518,000

Net revenue $121.4M vs $123.2M in Q2 2021; adjusted revenue up 3% excluding ReNu/NuCel.
Net income $8.7M ($0.07 diluted EPS) vs $20.7M ($0.15) a year ago; Adjusted net income $11.3M.
Advanced Wound Care rev $113.8M (+2%), Surgical & Sports Medicine $7.6M (-35%).
PuraPly rev $69.4M (+84%); non-PuraPly $52.0M (-39%).
FY2022 guidance: net revenue $465M-$490M; Adj. EBITDA $60M-$74M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.